Effect of Fiduxosin, an Antagonist Selective for α1A- and α1D-Adrenoceptors, on Intraurethral and Arterial Pressure Responses in Conscious Dogs

Fiduxosin is an α 1 -adrenoceptor antagonist with higher affinity for α 1A -adrenoceptors and for α 1D -adrenoceptors than for α 1B -adrenoceptors. Our hypothesis is that such a compound with higher affinity for subtypes implicated in the control of lower urinary tract function and lower affinity for a subtype implicated in the control of arterial pressure could result in a superior clinical profile for the treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction. The purpose of this study was to evaluate the potency and selectivity of fiduxosin for effects on prostatic intraurethral pressure (IUP) versus mean arterial pressure (MAP) relative to current clinical standards, terazosin and tamsulosin, in conscious dogs. Phenylephrine (PE)-induced increases in IUP and MAP were determined before and at various time points after an oral dose of each antagonist. Hypotensive potency was also determined. All three antagonists caused dose- and time-dependent blockade of the IUP and MAP pressor effects of PE. The IUP ED 50 values of fiduxosin, tamsulosin, and terazosin were 0.24, 0.004, and 0.23 mg/kg p.o., respectively. The corresponding MAP ED 50 values were 1.79, 0.006, and 0.09 mg/kg p.o. The rank order of IUP selectivity (ratio) was fiduxosin (7.5-fold), tamsulosin (1.5-fold), and terazosin (0.4 = 2.5-fold MAP-selective). Tamsulosin and terazosin caused dose-dependent hypotension, whereas no change in arterial pressure was seen after fiduxosin. These data, illustrating a superior selectivity profile of fiduxosin, are consistent with our hypothesis.

[1]  R. Kirby,et al.  The natural history of benign prostatic hyperplasia: what have we learned in the last decade? , 2000, Urology.

[2]  T. Tanaka,et al.  Identification of alpha1-adrenoceptor subtypes in the human prostatic urethra , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  H. Zhong,et al.  α1-Adrenoceptor subtypes , 1999 .

[4]  J. Gever,et al.  In vitroα1‐adrenoceptor pharmacology of Ro 70–0004 and RS‐100329, novel α1A‐adrenoceptor selective antagonists , 1999 .

[5]  R. Chess-Williams,et al.  Pharmacological characterization of A‐131701, a novel α1‐adrenoceptor antagonist selective for α1A‐ and α1D‐compared to α1B‐adrenoceptors , 1998 .

[6]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  W. Garraway,et al.  High prevalence of benign prostatic hypertrophy in the community , 1991, The Lancet.

[8]  A. Hancock,et al.  Pharmacological antagonism of α‐adrenergic agonist induced increases in canine intraurethral pressure in vivo , 1995 .

[9]  M. Michel,et al.  α‐Blockers and lower urinary tract function: more than smooth muscle relaxation? , 2000, BJU international.

[10]  A. Hancock,et al.  Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. , 1996, Pharmacology.

[11]  C. Chapple.  BHP Disease Management. Introduction and concluding remarks. , 1999, European urology.

[12]  N. Flavahan,et al.  α1-Adrenoceptor subclassification in vascular smooth muscle , 1986 .

[13]  I. Muramatsu,et al.  Pharmacological subclassification of α1‐adrenoceptors in vascular smooth muscle , 1990 .

[14]  C. Chapple,et al.  Introduction and Concluding Remarks , 2000, European Urology.

[15]  C. D. Richardson,et al.  Alpha1-adrenergic receptor subtypes in human detrusor. , 1998, The Journal of urology.

[16]  C G Chute,et al.  Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. , 1995, The Journal of urology.

[17]  G. Johnston,et al.  Prostatic disorders in the dog. , 2000, Animal reproduction science.

[18]  A. Hancock,et al.  Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[19]  A. Hancock.  α1 Adrenoceptor subtypes: A synopsis of their pharmacology and molecular biology , 1996 .

[20]  J. Debernardis,et al.  A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. , 1995, The Journal of pharmacology and experimental therapeutics.

[21]  H. Lepor,et al.  Binding and functional properties of alpha 1 adrenoceptors and area density of smooth muscle in the canine prostate. , 1992, The Journal of urology.

[22]  A. Corbett,et al.  Depressant effects of hypoxia and hypoglycaemia on neuro‐effector transmission of guinea‐pig intestine studied in vitro with a pharmacological model , 1997, British journal of pharmacology.

[23]  T. Ogasawara,et al.  NS-49, an α1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs , 1996 .

[24]  P. Molinoff,et al.  International Union of Pharmacology nomenclature of adrenoceptors. , 1994, Pharmacological reviews.

[25]  T. Branchek,et al.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. , 1994, Molecular pharmacology.

[26]  H A Guess,et al.  Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. , 1994, Urology.

[27]  A. Hancock,et al.  Actions of A-131701, a novel, selective antagonist for alpha-1A compared with alpha-1B adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity. , 1998, The Journal of pharmacology and experimental therapeutics.

[28]  H. Lepor,et al.  A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  T. Philipp,et al.  Differential vascular α1‐adrenoceptor antagonism by tamsulosin and terazosin , 1999 .

[30]  M. Michel,et al.  Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. , 1998, British journal of clinical pharmacology.

[31]  T. Stamey,et al.  RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. , 1996, Molecular pharmacology.

[32]  H. Lepor,et al.  The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle , 1993, The Prostate.

[33]  M. Williams,et al.  Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties. , 2002, The Journal of pharmacology and experimental therapeutics.

[34]  M. Marberger,et al.  A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction , 1999, European Urology.

[35]  M. Tuck.  The sympathetic nervous system in essential hypertension. , 1986, American heart journal.

[36]  A. Hancock,et al.  Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. , 1997, The Journal of pharmacology and experimental therapeutics.